Rangering i aksjer
#25180
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to... Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.
Aksjekurs
$1.95
Sist synkronisert: 2022-07-29
Handel Cortexyme, Inc. (CRTX)
Pris CRTX pris med markedsverdi på B
Markedsverdi av Cortexyme, Inc.(CRTX)
Markedsverdi: $52.48M
Per August 2026 har Cortexyme, Inc. en markedsverdi på $52.48M. Dette gjør Cortexyme, Inc. til det 25180th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Cortexyme, Inc. fra 2019 til 2026
CRTX sammenlignet med topp 5 mest populære stocks
| Pris på CRTX |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.257T
|
+10,017,403.34%
|
|
|
|
|
$4.599T
|
+8,763,132.61%
|
|
|
|
|
$4.107T
|
+7,825,441.76%
|
|
|
|
|
$3.577T
|
+6,816,746.16%
|
|
|
|
|
$2.807T
|
+5,349,526.26%
|
